Kidney Cancer Coverage from Every Angle

MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study

By: Vanessa A. Carter, BS
Posted: Wednesday, August 4, 2021

A study conducted by Cristina Suárez Rodriguez, MD, of Vall d’ Hebron University Hospital, Barcelona, and colleagues found that the combination of the MET inhibitor savolitinib and the PD-L1 inhibitor durvalumab demonstrates clinical activity in patients with MET-driven metastatic papillary renal cancer. The efficacy of this combination was evaluated, with a phase III randomized study planned, and their results were presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4511).

This single-arm, phase I/II trial focused on 42 patients with MET-driven metastatic papillary renal cancer. Participants were administered 1,500 mg of durvalumab every 4 weeks and 600 mg of savolitinib daily. MET DNA alterations were defined as MET kinase domain mutations, MET or HGF amplification, or chromosome 7 gain.

Of the total participants, 41 underwent treatment, with a median follow-up of 26.8 months. The confirmed response rate was 29%, and the median progression-free survival was 4.9 months. Among the cohort, 14 patients had MET-driven disease, with 10 having received no previous systemic therapy; one patient had PD-L1–positive disease.

According to the International Metastatic Renal Cell Carcinoma Database Consortium, eight patients with MET-driven tumors had intermediate-risk disease, five had good-risk disease, and one had poor-risk disease. The confirmed response rate was 57%, with a duration of response of 9.4 months. The median overall survival and progression-free survival for these participants were 27.4 months and 9.4 months, respectively, and no new safety signals were observed.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.